The clampdown happened earlier this year when the Supreme Court, in response to numerous public interest lawsuits, suspended 157 clinical trials. Indian standards had been seen by some as being rather loose but the legal response has largely frozen what was becoming a boom sector for the country. Mahima Datla, MD of Biological E, the vaccine producer, said that the shutdown 'will kill drug development in India. Companies will do their studies elsewhere and it is the Indian consumer who will suffer'. Source: The Financial Times